Thalamus
PrivateLast Round
Series B
Jan 30, 2025
Est. Valuation
$45M
Total Funding Raised
$44.48M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Thalamus operates in Enterprise Software and is based in San Francisco, California. Its latest recorded funding round was a Series B round in January 2025.
Thalamus is a software as a service company that provides a cloud-based interview management platform for graduate medical education training programs.
Sector
Enterprise Software
Verticals
Vertical SaaS, HR, Healthcare Analytics, Workflow Automation
Business Model
B2B
Customer Profile
Freemium, Subscription SaaS, Data as a Service, Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Thalamus Comparables
Compare Thalamus with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| The Tenth Nerve, LLC | 79% | |
| Druksys, LLC | 79% | |
| Liaison International | 78% |
For institutional investors. Book with your work email.
Thalamus Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jan 30, 2025 | ||||
| Series A | Feb 17, 2022 | ||||
| Seed | Dec 12, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Thalamus Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Fresco Capital | Seed, Series B |
| 37 Angels | Seed |
| LAUNCH | Seed, Series B |
| Kapor Capital | Seed, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors grew 131% MoM, reaching 214.9K.
- Nov 7, 2025
Monthly visitors grew 689% MoM, reaching 3.8M.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- partners_withSep 10, 2026
The lawsuit alleges that Thalamus partners with APGO, the American Medical Association, and Hammoud on a pilot project for the 2020-21 application cycle, with Hammoud serving as principal investigator and having full access to Thalamus's products.
For institutional investors. Book with your work email.
Thalamus Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Thalamus's valuation, stock price, and market status.
Is Thalamus a public or private company?
Thalamus is a private company.
What is the current stock price of Thalamus?
Thalamus is a private company, so its shares have no public market price. Caplight tracks Thalamus's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Thalamus worth (valuation)?
Thalamus's valuation is estimated at $45.0M based on funding round data.
Can I buy Thalamus stock?
Thalamus shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Thalamus's last funding round?
Thalamus's most recent funding round was Series B on January 30, 2025.
Who are the main investors in Thalamus?
Key investors in Thalamus include Fresco Capital, 37 Angels, LAUNCH, Kapor Capital.
Will Thalamus IPO soon?
No public IPO plans have been announced for Thalamus.
How can I track Thalamus secondary market activity?
Caplight tracks bids, offers, and trades in Thalamus's shares on secondary markets.